Russian Ministry of Health approved Areplivir for the treatment of coronavirus infection
Promomed 26 June 2020
Promomed Group has received a marketing authorization certificate for the manufacture of Areplivir, antiviral drug effective for COVID-19 developed by the company's specialists at the Promomed’s production site Biokhimik JSC.
This event will change the course of epidemic and create a reliable protection against the threat of the predicted «second wave» of the coronavirus pandemic.
Biokhimik is fully ready for large-scale production of Areplivir: the company is able to produce up to one million packages per month, which will cover all the demand of medical institutions in Russia.
Currently, Areplivir is at the final stage of clinical trials that in total enroll 210 voluntarily participating patients with confirmed coronavirus infection undergoing treatment in medical institutions in Saransk, Moscow, and St. Petersburg.
The results of the third phase of clinical trials of Areplivir demonstrate its effectiveness exceeding 90%. It is confirmed that Areplivir decreases the duration of the disease from nine to four days compared to the control group. In biological samples of 70 percent of patients taking Areplivir the virus was absent as early as on the fourth day.
Healthcare professionals who use Areplivir in their practice also stress that it demonstrates high efficacy even without combined therapy including anti-inflammatory products and antibiotics. Doctors recommend prescribing Areplivir to patients with moderate to mild forms of disease in the first 48 hours of treatment.
This event will change the course of epidemic and create a reliable protection against the threat of the predicted «second wave» of the coronavirus pandemic.
Biokhimik is fully ready for large-scale production of Areplivir: the company is able to produce up to one million packages per month, which will cover all the demand of medical institutions in Russia.
Currently, Areplivir is at the final stage of clinical trials that in total enroll 210 voluntarily participating patients with confirmed coronavirus infection undergoing treatment in medical institutions in Saransk, Moscow, and St. Petersburg.
The results of the third phase of clinical trials of Areplivir demonstrate its effectiveness exceeding 90%. It is confirmed that Areplivir decreases the duration of the disease from nine to four days compared to the control group. In biological samples of 70 percent of patients taking Areplivir the virus was absent as early as on the fourth day.
Healthcare professionals who use Areplivir in their practice also stress that it demonstrates high efficacy even without combined therapy including anti-inflammatory products and antibiotics. Doctors recommend prescribing Areplivir to patients with moderate to mild forms of disease in the first 48 hours of treatment.
Another important result of clinical studies is the absence of new «safety signals» – previously unknown adverse effects of Areplivir.
All these features allow us to call Areplivir a «drug of hope and salvation».
The development of Areplivir has become part of a large-scale antiviral program carried out by specialists of Promomed Group and the Biokhimik JSC production site. The drug was developed in the shortest possible time, and the full cycle process for production of Areplivir was implemented promptly. The drug is based on favipiravir as active ingredient, which blocks the virus reproduction in human cells and thereby prevents the spread of infection in the body.
The drug will be available for patients treated in a hospital under medical supervision. The company's specialists believe that this drug will allow Russian citizens to cope with the infection more efficiently, easily and quickly. The company is also considering export potential of Areplivir, but at the moment the company's priority is the health of Russian residents.
For reference: the company has been at the forefront of the fight since the first days of the pandemic. Biokhimik produces all antibacterial agents approved by the Russian Ministry of Health in the guidelines for treatment of coronavirus infection. In the epidemic circumstances, the company equips doctors with the most effective medicines in the required quantity, making a significant contribution to the elimination of the national threat.
All these features allow us to call Areplivir a «drug of hope and salvation».
The development of Areplivir has become part of a large-scale antiviral program carried out by specialists of Promomed Group and the Biokhimik JSC production site. The drug was developed in the shortest possible time, and the full cycle process for production of Areplivir was implemented promptly. The drug is based on favipiravir as active ingredient, which blocks the virus reproduction in human cells and thereby prevents the spread of infection in the body.
The drug will be available for patients treated in a hospital under medical supervision. The company's specialists believe that this drug will allow Russian citizens to cope with the infection more efficiently, easily and quickly. The company is also considering export potential of Areplivir, but at the moment the company's priority is the health of Russian residents.
For reference: the company has been at the forefront of the fight since the first days of the pandemic. Biokhimik produces all antibacterial agents approved by the Russian Ministry of Health in the guidelines for treatment of coronavirus infection. In the epidemic circumstances, the company equips doctors with the most effective medicines in the required quantity, making a significant contribution to the elimination of the national threat.
